

1 ROB BONTA
Attorney General of California
2 MATTHEW M. DAVIS
Supervising Deputy Attorney General
3 LEANNA E. SHIELDS
Deputy Attorney General
4 State Bar No. 239872
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 738-9401
7 Facsimile: (619) 645-2061

8 *Attorneys for Complainant*

9

10
11
12

**BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

13
14
15
16
17
18

In the Matter of the Accusation Against:

EDWARD HARRY NAVAKAS, M.D.
1630 E. Main Street
El Cajon, CA 92021

**Physician's and Surgeon's Certificate
No. G 88320,**

Respondent.

Case No. 800-2022-088933

A C C U S A T I O N

19
20

Complainant alleges:

21

PARTIES

22
23
24
25
26
27
28

1. Reji Varghese (Complainant) brings this Accusation solely in his official capacity as the Executive Director of the Medical Board of California, Department of Consumer Affairs (Board).

2. On or about August 1, 2008, the Medical Board issued Physician's and Surgeon's Certificate No. G 88320 to Edward Harry Navakas, M.D. (Respondent). The Physician's and Surgeon's Certificate was in full force and effect at all times relevant to the charges brought herein and will expire on August 31, 2024, unless renewed.

JURISDICTION

1
2 3. This Accusation is brought before the Board, under the authority of the following
3 laws. All section references are to the Business and Professions Code (Code) unless otherwise
4 indicated.

5 4. Section 2227 of the Code states, in pertinent part:

6 (a) A licensee whose matter has been heard by an administrative law judge of
7 the Medical Quality Hearing Panel as designated in Section 11371 of the Government
8 Code, or whose default has been entered, and who is found guilty, or who has entered
9 into a stipulation for disciplinary action with the board, may, in accordance with the
10 provisions of this chapter:

11 (1) Have his or her license revoked upon order of the board.

12 (2) Have his or her right to practice suspended for a period not to exceed one
13 year upon order of the board.

14 (3) Be placed on probation and be required to pay the costs of probation
15 monitoring upon order of the board.

16 (4) Be publicly reprimanded by the board. The public reprimand may include a
17 requirement that the licensee complete relevant educational courses approved by the
18 board.

19 (5) Have any other action taken in relation to discipline as part of an order of
20 probation, as the board or an administrative law judge may deem proper.

21 ...

22 5. Section 2234 of the Code, states, in pertinent part:

23 The board shall take action against any licensee who is charged with
24 unprofessional conduct. In addition to other provisions of this article, unprofessional
25 conduct includes, but is not limited to, the following:

26 (a) Violating or attempting to violate, directly or indirectly, assisting in or
27 abetting the violation of, or conspiring to violate any provision of this chapter.

28 ...

(c) Repeated negligent acts. To be repeated, there must be two or more
negligent acts or omissions. An initial negligent act or omission followed by a
separate and distinct departure from the applicable standard of care shall constitute
repeated negligent acts.

(1) An initial negligent diagnosis followed by an act or omission medically
appropriate for that negligent diagnosis of the patient shall constitute a single
negligent act.

///

1 (2) When the standard of care requires a change in the diagnosis, act, or
2 omission that constitutes the negligent act described in paragraph (1), including, but
3 not limited to, a reevaluation of the diagnosis or a change in treatment, and the
4 licensee's conduct departs from the applicable standard of care, each departure
5 constitutes a separate and distinct breach of the standard of care.

6 ...

7 6. Section 2238 of the Code states:

8 A violation of any federal statute or federal regulation or any of the statutes or
9 regulations of this state regulating dangerous drugs or controlled substances
10 constitutes unprofessional conduct.

11 7. From January 1, 2017, through June 30, 2021,¹ section 11165.4 of the Health and
12 Safety Code stated, in pertinent part:²

13 (a)(1)(A)(i) A health care practitioner authorized to prescribe, order, administer,
14 or furnish a controlled substance shall consult the CURES database to review a
15 patient's controlled substance history before prescribing a Schedule II, Schedule III,
16 or Schedule IV controlled substance to the patient for the first time and at least once
17 every four months thereafter if the substance remains part of the treatment of the
18 patient.

19 ...

20 (e) This section is not operative until six months after the Department of Justice
21 certifies that the CURES database is ready for statewide use and that the department
22 has adequate staff, which, at a minimum, shall be consistent with the appropriation
23 authorized in Schedule (6) of Item 0820-001-0001 of the Budget Act of 2016
24 (Chapter 23 of the Statutes of 2016), user support, and education. The department
25 shall notify the Secretary of State and the office of the Legislative Counsel of the date
26 of that certification.

27 8. Since July 1, 2021, section 11165.4 of the Health and Safety Code states, in pertinent
28 part:

(a)(1)(A)(i) A health care practitioner authorized to prescribe, order, administer,
or furnish a controlled substance shall consult the patient activity report or
information from the patient activity report obtained from the CURES database to
review a patient's controlled substance history for the past 12 months before

¹ Health and Safety Code section 11165.4 was amended on January 1, 2020, however the provisions of subdivisions (a)(1)(A)(i) and (e) remained unchanged until July 1, 2021.

² The Controlled Substance Utilization Review and Evaluation System (CURES) was certified for statewide use by the Department of Justice (DOJ) on April 2, 2018. Therefore, the mandate to consult CURES prior to prescribing, ordering, administering, or furnishing a Schedule II-IV controlled substance became effective October 2, 2018.

1 11. Alprazolam, brand name Xanax, is a Schedule IV controlled substance pursuant to
2 Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to
3 Business and Professions Code section 4022. When properly prescribed and indicated,
4 alprazolam is an anti-anxiety medication in the benzodiazepine class. According to the DEA,
5 benzodiazepines, such as alprazolam, are considered drugs of abuse. (Drugs of Abuse, A DEA
6 Resource Guide, 2017 edition, at p. 59.) The Food and Drug Administration has issued a black
7 box warning for alprazolam which states, the “concomitant use of benzodiazepines with opioids
8 may result in profound sedation, respiratory depression, coma, and death...benzodiazepines
9 expose users to risk of abuse, misuse, and addiction, can lead to overdose or death,...assess risk
10 for abuse, misuse, and addiction before prescribing and throughout [treatment]...”

11 12. Clonazepam, brand name Klonopin, is a Schedule IV controlled substance pursuant to
12 Health and Safety Code section 11057, and a dangerous drug pursuant to Business and
13 Professions Code section 4022. When properly prescribed and indicated, clonazepam is an
14 anticonvulsant medication in the benzodiazepine class commonly prescribed for seizure disorders
15 and panic disorders. According to the DEA, benzodiazepines, such as clonazepam, are
16 considered drugs of abuse. (Drugs of Abuse, A DEA Resource Guide, 2017 edition, at p. 59.)
17 The Food and Drug Administration has issued a black box warning for clonazepam which states,
18 the “concomitant benzodiazepine use with opioids may result in profound sedation, respiratory
19 depression, coma, and death...benzodiazepines expose users to risk of abuse, misuse, and
20 addiction, can lead to overdose or death,...assess risk for abuse, misuse, and addiction before
21 prescribing and throughout [treatment]...”

22 13. The Controlled Substance Utilization Review and Evaluation System (CURES) is a
23 program operated by the California Department of Justice (DOJ) to assist health care practitioners
24 in their efforts to ensure appropriate prescribing of controlled substances, and law enforcement
25 and regulatory agencies in their efforts to control diversion and abuse of controlled substances.
26 (Health & Saf. Code, § 11165.) California law requires dispensing pharmacies to report to the
27 DOJ the dispensing of Schedule II, III, and IV controlled substances as soon as reasonably
28 possible after the prescriptions are filled. (Health & Saf. Code, § 11165, subd. (d).) It is

1 important to note that the history of controlled substances dispensed to a specific patient based on
2 the data contained in CURES is available to a health care practitioner who is treating that patient.
3 (Health & Saf. Code, § 11165.1, subd. (a).)

4 14. Hydromorphone, brand name Dilaudid, is a Schedule II controlled substance pursuant
5 to Health and Safety Code section 11055, subdivision (b), and a dangerous drug pursuant to
6 Business and Professions Code section 4022. When properly prescribed and indicated,
7 hydromorphone is an opioid analgesic commonly prescribed for the treatment of moderate to
8 severe pain. According to the DEA, opioids, such as hydromorphone, are considered drugs of
9 abuse. (Drugs of Abuse, A DEA Resource Guide, 2017 edition, at p. 43.) The Food and Drug
10 Administration has issued a black box warning for hydromorphone which warns of “risk of
11 addiction, abuse, misuse, which can lead to overdose and death; assess opioid abuse or addiction
12 risk prior to prescribing...concomitant opioid use with benzodiazepines or other CNS
13 depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and
14 death; reserve concomitant use for patients with inadequate alternative treatment options.”

15 15. Methadone is a Schedule II controlled substance pursuant to Health and Safety Code
16 section 11055, subdivision (c), and a dangerous drug pursuant to Business and Professions Code
17 section 4022. When properly prescribed and indicated, methadone is a synthetic opioid analgesic
18 commonly prescribed for opioid dependence and moderate to severe pain. According to the
19 DEA, opioids, such as methadone, are considered drugs of abuse. (Drugs of Abuse, A DEA
20 Resource Guide, 2017 edition, at p. 44.) The Food and Drug Administration has issued a black
21 box warning for methadone which warns of “risk of addiction, abuse, misuse, which can lead to
22 overdose and death; assess opioid abuse or addiction risk prior to prescribing...concomitant
23 opioid use with benzodiazepines or other CNS depressants, including alcohol, may result in
24 profound sedation, respiratory depression, coma, and death; reserve concomitant use for patients
25 with inadequate alternative treatment options.”

26 16. Norco is a brand name for the drug combination of hydrocodone and acetaminophen.
27 Hydrocodone is a Schedule II controlled substance pursuant to Health and Safety Code section
28 11055, subdivision (b), and a dangerous drug pursuant to Business and Professions Code section

1 4022. When properly prescribed and indicated, hydrocodone is an opioid commonly prescribed
2 for the treatment of moderate to severe pain. According to the DEA, opioids, such as
3 hydrocodone, are considered drugs of abuse. (Drugs of Abuse, A DEA Resource Guide, 2017
4 edition, at pp. 43-47.) The Food and Drug Administration has issued a black box warning for
5 hydrocodone which warns of “risk of addiction, abuse, and misuse, which can lead to overdose
6 and death... concomitant opioid use with benzodiazepines or other CNS depressants, including
7 alcohol, may result in profound sedation, respiratory depression, coma, and death; reserve
8 concomitant use for patients with inadequate alternative treatment options.”

9 17. Suboxone is a brand name for buprenorphine/naloxone, a Schedule III controlled
10 substance pursuant to Health and Safety Code section 11055, subdivision (c), and a dangerous
11 drug pursuant to Business and Professions Code section 4022. When properly prescribed and
12 indicated, Suboxone is commonly prescribed for the treatment of opioid dependence.

13 **FIRST CAUSE FOR DISCIPLINE**

14 **(Repeated Negligent Acts)**

15 18. Respondent has subjected his Physician’s and Surgeon’s Certificate No. G 88320 to
16 disciplinary action under sections 2227 and 2234, as defined by section 2234, subdivision (c), of
17 the Code, in that he committed repeated negligent acts in his care and treatment of Patients A, B,
18 C, and D, as more particularly alleged hereinafter.

19 **Patient A**³

20 19. On or about February 13, 2018, Patient A, a then 49-year-old male, first sought
21 treatment with Respondent. According to records, Patient A was diagnosed with generalized
22 anxiety disorder, major depressive disorder, insomnia, and chronic pain. According to records,
23 Patient A regularly received and filled prescriptions issued by Respondent for clonazepam.

24 20. According to records, Patient A had a history of alcohol abuse and throughout
25 Respondent’s care and treatment, Patient A also received regular prescriptions from other medical

26 _____
27 ³ Patient identities have been withheld to maintain patient confidentiality. The patients’ identities
28 are known to Respondent or will be disclosed to Respondent upon receipt of a duly issued request for
discovery and in accordance with Government Code section 11507.6.

1 treatment providers for other controlled substances, including, but not limited to: hydromorphone,
2 methadone, Norco, and Suboxone.

3 21. From on or about February 13, 2018, through on or about November 5, 2021,
4 according to records, Patient A had visits with, and was assessed by, Respondent on
5 approximately seven (7) occasions, including, but not limited to: February 13, 2018; June 6,
6 2019; March 26, 2020; June 25, 2020; May 21, 2021; August 13, 2021; and November 5, 2021.

7 22. According to records, Patient A did not appear to his scheduled appointments with
8 Respondent on approximately three (3) occasions, including, but not limited to: January 16, 2020,
9 February 28, 2020, and March 3, 2020.

10 23. From on or about February 13, 2018, through on or about November 5, 2021,
11 according to records, Respondent consulted the CURES database to review Patient A's patient
12 activity report on four (4) occasions, including but not limited to: June 26, 2018; December 27,
13 2018; June 6, 2019; and January 16, 2020.

14 24. From on or about January 10, 2019, through on or about November 5, 2021,
15 according to the CURES database, Patient A filled prescriptions issued by Respondent for
16 clonazepam (1 mg), as follows:

Date Filled	Drug Name	Strength	Days Supply	Quantity	Pharmacy Rx No.
1/10/2019	Clonazepam	1 mg	30	60	2049219
2/28/2019	Clonazepam	1 mg	30	60	2049219
4/4/2019	Clonazepam	1 mg	30	60	2112525
5/21/2019	Clonazepam	1 mg	30	60	2112525
6/18/2019	Clonazepam	1 mg	30	60	2049219
7/19/2019	Clonazepam	1 mg	30	60	2157901
8/29/2019	Clonazepam	1 mg	30	60	2157901
10/11/2019	Clonazepam	1 mg	30	60	2157901
1/9/2020	Clonazepam	1 mg	30	60	2311789
3/2/2020	Clonazepam	1 mg	30	60	2311789

Date Filled	Drug Name	Strength	Days Supply	Quantity	Pharmacy Rx No.
3/31/2020	Clonazepam	1 mg	30	60	2374902
6/25/2020	Clonazepam	1 mg	30	60	2431119
11/29/2020	Clonazepam	1 mg	30	60	2431119
4/15/2021	Clonazepam	1 mg	30	60	2630886
5/21/2021	Clonazepam	1 mg	30	30	2657006
6/29/2021	Clonazepam	1 mg	30	30	2677052
7/26/2021	Clonazepam	1 mg	30	30	2677052
8/30/2021	Clonazepam	1 mg	30	30	2732593
9/30/2021	Clonazepam	1 mg	30	30	1737437
11/2/2021	Clonazepam	1 mg	30	30	1737437

25. Respondent committed repeated negligent acts in his care and treatment of Patient A, including, but not limited to, the following:

- A. Paragraphs 19 through 24, above, are hereby incorporated by reference and realleged as if fully set forth herein;
- B. Issuing a prescription for clonazepam to Patient A on or about January 9, 2020, when Respondent's last review of Patient A's prescription history in the CURES database was on or about June 6, 2019;
- C. Issuing a prescription for clonazepam to Patient A on or about June 25, 2020, when Respondent's last review of Patient A's prescription history in the CURES database was on or about June 6, 2019;
- D. Issuing a prescription for clonazepam to Patient A on or about April 15, 2021, when Respondent's last review of Patient A's prescription history in the CURES database was on or about June 6, 2019;

///

///

1 E. Issuing a prescription for clonazepam to Patient A on or about May 21, 2021,
2 when Respondent's last review of Patient A's prescription history in the CURES
3 database was on or about June 6, 2019;

4 F. Issuing a prescription for clonazepam to Patient A on or about June 29, 2021,
5 when Respondent's last review of Patient A's prescription history in the CURES
6 database was on or about June 6, 2019;

7 G. Issuing a prescription for clonazepam to Patient A on or about August 30, 2021,
8 when Respondent's last review of Patient A's prescription history in the CURES
9 database was on or about June 6, 2019;

10 H. Issuing a prescription for clonazepam to Patient A on or about September 30,
11 2021, when Respondent's last review of Patient A's prescription history in the
12 CURES database was on or about June 6, 2019;

13 I. Issuing a prescription for clonazepam to Patient A on or about January 10,
14 2019, when Respondent's last visit and/or assessment of Patient A was on or about
15 February 13, 2018;

16 J. Issuing a prescription for clonazepam to Patient A on or about April 4, 2019,
17 when Respondent's last visit and/or assessment of Patient A was on or about
18 February 13, 2018;

19 K. Issuing a prescription for clonazepam to Patient A on or about January 9, 2020,
20 when Respondent's last visit and/or assessment of Patient A was on or about June 6,
21 2019; and

22 L. Issuing a prescription for clonazepam to Patient A on or about April 15, 2021,
23 when Respondent's last visit and/or assessment of Patient A was on or about June 25,
24 2020.

25 **Patient B**

26 26. On or about February 22, 2018, Patient B, a then 25-year-old male, first sought
27 treatment with Respondent. According to records, Patient B was diagnosed with ADHD.
28 According to records, Patient B regularly received and filled prescriptions issued by Respondent

1 for Adderall in two forms, amphetamine salt combo (10 mg) for immediate release and mixed
2 amphetamine salt (20 mg) for extended release.

3 27. From on or about February 22, 2018, through on or about March 18, 2022, according
4 to records, Patient B had visits with, and was assessed by, Respondent on approximately fifteen
5 (15) occasions, including, but not limited to: February 22, 2018; May 16, 2018; August 17, 2018;
6 November 8, 2018; February 7, 2019; January 16, 2020; May 15, 2020; June 5, 2020; August 28,
7 2020; October 16, 2020; January 8, 2021; June 25, 2021; September 17, 2021; December 17,
8 2021; and March 18, 2022.

9 28. From on or about February 22, 2018, through on or about March 18, 2022, according
10 to records, Respondent consulted the CURES database to review Patient B's patient activity
11 report on fourteen (14) occasions, including but not limited to: May 16, 2018; August 17, 2018;
12 November 8, 2018; February 7, 2019; June 6, 2019; July 11, 2019; August 8, 2019; September
13 19, 2019; December 13, 2019; January 9, 2020; January 16, 2020; March 12, 2020; May 15,
14 2020; and August 28, 2020.

15 29. On or about November 8, 2018, Respondent noted observing "odd dispensing" from
16 his review of Patient B's CURES patient activity report.

17 30. From on or about January 25, 2019, through on or about April 29, 2022, according to
18 the CURES database, Patient B filled prescriptions issued by Respondent for amphetamine salt
19 combo (10 mg) and mixed amphetamine salt (20 mg), as follows:

Date Filled	Drug Name	Strength	Days Supply	Quantity	Pharmacy Rx No.
1/25/2019	Mixed Amphetamine Salt	20 mg	30	30	1160354
1/25/2019	Mixed Amphetamine Salt	20 mg	30	30	1160354
2/1/2019	Amphetamine Salt Combo	10 mg	29	58	1161958
2/26/2019	Mixed Amphetamine Salt	20 mg	30	30	949670
3/5/2019	Amphetamine Salt Combo	10 mg	30	60	1169022
3/31/2019	Mixed Amphetamine Salt	20 mg	30	30	1174848

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Date Filled	Drug Name	Strength	Days Supply	Quantity	Pharmacy Rx No.
4/6/2019	Amphetamine Salt Combo	10 mg	30	60	1174851
4/30/2019	Mixed Amphetamine Salt	20 mg	30	30	1148808
5/7/2019	Amphetamine Salt Combo	10 mg	30	60	1150962
6/7/2019	Mixed Amphetamine Salt	20 mg	30	30	1158910
6/7/2019	Amphetamine Salt Combo	10 mg	30	30	1158909
7/11/2019	Amphetamine Salt Combo	10 mg	30	30	1166837
7/11/2019	Mixed Amphetamine Salt	20 mg	30	30	1166838
8/9/2019	Amphetamine Salt Combo	10 mg	30	30	1174412
8/9/2019	Mixed Amphetamine Salt	20 mg	30	30	1174411
9/19/2019	Amphetamine Salt Combo	10 mg	30	30	1184678
9/19/2019	Mixed Amphetamine Salt	20 mg	30	30	1184677
10/17/2019	Mixed Amphetamine Salt	20 mg	30	30	1192303
10/17/2019	Amphetamine Salt Combo	10 mg	30	30	1192302
11/15/2019	Mixed Amphetamine Salt	20 mg	30	30	1200313
11/15/2019	Amphetamine Salt Combo	10 mg	30	30	1200521
12/13/2019	Mixed Amphetamine Salt	20 mg	30	30	1207782
12/13/2019	Amphetamine Salt Combo	10 mg	30	30	1207771
1/13/2020	Mixed Amphetamine Salt	20 mg	30	30	1214579
1/13/2020	Amphetamine Salt Combo	10 mg	30	30	1214582
2/14/2020	Mixed Amphetamine Salt	20 mg	30	30	1119820
2/17/2020	Amphetamine Salt Combo	10 mg	30	30	1120132
3/16/2020	Mixed Amphetamine Salt	20 mg	30	30	1233219
3/16/2020	Amphetamine Salt Combo	10 mg	60	60	1233222
4/22/2020	Amphetamine Salt Combo	10 mg	30	60	1243204

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Date Filled	Drug Name	Strength	Days Supply	Quantity	Pharmacy Rx No.
4/23/2020	Mixed Amphetamine Salt	20 mg	30	30	1243372
7/24/2020	Mixed Amphetamine Salt	20 mg	30	30	1265167
7/26/2020	Amphetamine Salt Combo	10 mg	30	60	1265168
8/30/2020	Mixed Amphetamine Salt	20 mg	30	30	1273943
8/30/2020	Amphetamine Salt Combo	10 mg	30	60	1273942
10/2/2020	Amphetamine Salt Combo	10 mg	30	60	1282987
10/6/2020	Mixed Amphetamine Salt	20 mg	30	30	1282986
11/22/2020	Mixed Amphetamine Salt	20 mg	6	6	1296001
11/22/2020	Amphetamine Salt Combo	10 mg	8	16	1296002
12/7/2020	Mixed Amphetamine Salt	20 mg	6	6	1298379
12/7/2020	Amphetamine Salt Combo	10 mg	8	16	1298378
12/19/2020	Mixed Amphetamine Salt	20 mg	30	30	1302704
12/19/2020	Amphetamine Salt Combo	10 mg	15	30	1302703
1/25/2021	Mixed Amphetamine Salt	20 mg	30	30	105786
1/25/2021	Amphetamine Salt Combo	10 mg	15	30	105803
2/23/2021	Mixed Amphetamine Salt	20 mg	30	30	112600
2/23/2021	Amphetamine Salt Combo	10 mg	15	30	112598
3/25/2021	Mixed Amphetamine Salt	20 mg	30	30	118475
3/25/2021	Amphetamine Salt Combo	10 mg	15	30	118476
5/7/2021	Mixed Amphetamine Salt	20 mg	30	30	124139
6/4/2021	Amphetamine Salt Combo	10 mg	15	30	112602
6/4/2021	Mixed Amphetamine Salt	20 mg	30	30	127439
6/26/2021	Amphetamine Salt Combo	10 mg	30	60	130065
7/5/2021	Mixed Amphetamine Salt	20 mg	30	30	130826

Date Filled	Drug Name	Strength	Days Supply	Quantity	Pharmacy Rx No.
8/9/2021	Amphetamine Salt Combo	10 mg	30	30	134725
8/9/2021	Mixed Amphetamine Salt	20 mg	30	30	134724
8/24/2021	Amphetamine Salt Combo	10 mg	25	50	136205
9/27/2021	Amphetamine Salt Combo	10 mg	25	50	139495
10/26/2021	Mixed Amphetamine Salt	20 mg	30	30	141478
12/27/2021	Amphetamine Salt Combo	10 mg	25	50	149713
12/27/2021	Mixed Amphetamine Salt	20 mg	30	30	149712
3/1/2022	Amphetamine Salt Combo	10 mg	30	60	157477
3/1/2022	Mixed Amphetamine Salt	20 mg	30	30	157478
3/28/2022	Mixed Amphetamine Salt	20 mg	30	30	159928
3/28/2022	Amphetamine Salt Combo	10 mg	30	60	160581
4/29/2022	Amphetamine Salt Combo	10 mg	30	60	164689
4/29/2022	Mixed Amphetamine Salt	20 mg	30	30	164688

31. Respondent committed repeated negligent acts in his care and treatment of Patient B, including, but not limited to, the following:

- A. Paragraphs 26 through 30, above, are hereby incorporated by reference and realleged as if fully set forth herein;
- B. Issuing prescriptions for Adderall to Patient B on or about February 23, 2021, when Respondent's last review of Patient B's prescription history in the CURES database was on or about August 28, 2020;
- C. Issuing prescriptions for Adderall to Patient B on or about March 25, 2021, when Respondent's last review of Patient B's prescription history in the CURES database was on or about August 28, 2020;

///

///

1 D. Issuing prescriptions for Adderall to Patient B on or about May 7, 2021, when
2 Respondent's last review of Patient B's prescription history in the CURES database
3 was on or about August 28, 2020;

4 E. Issuing prescriptions for Adderall to Patient B on or about June 4, 2021, when
5 Respondent's last review of Patient B's prescription history in the CURES database
6 was on or about August 28, 2020;

7 F. Issuing prescriptions for Adderall to Patient B on or about June 26, 2021, when
8 Respondent's last review of Patient B's prescription history in the CURES database
9 was on or about August 28, 2020;

10 G. Issuing prescriptions for Adderall to Patient B on or about July 5, 2021, when
11 Respondent's last review of Patient B's prescription history in the CURES database
12 was on or about August 28, 2020;

13 H. Issuing prescriptions for Adderall to Patient B on or about August 9, 2021,
14 when Respondent's last review of Patient B's prescription history in the CURES
15 database was on or about August 28, 2020;

16 I. Issuing prescriptions for Adderall to Patient B on or about August 24, 2021,
17 when Respondent's last review of Patient B's prescription history in the CURES
18 database was on or about August 28, 2020;

19 J. Issuing prescriptions for Adderall to Patient B on or about September 27, 2021,
20 when Respondent's last review of Patient B's prescription history in the CURES
21 database was on or about August 28, 2020;

22 K. Issuing prescriptions for Adderall to Patient B on or about October 26, 2021,
23 when Respondent's last review of Patient B's prescription history in the CURES
24 database was on or about August 28, 2020;

25 L. Issuing prescriptions for Adderall to Patient B on or about December 27, 2021,
26 when Respondent's last review of Patient B's prescription history in the CURES
27 database was on or about August 28, 2020;

28 ///

1 M. Issuing prescriptions for Adderall to Patient B on or about March 1, 2022, when
2 Respondent's last review of Patient B's prescription history in the CURES database
3 was on or about August 28, 2020;

4 N. Issuing prescriptions for Adderall to Patient B on or about March 28, 2022,
5 when Respondent's last review of Patient B's prescription history in the CURES
6 database was on or about August 28, 2020;

7 O. Issuing prescriptions for Adderall to Patient B on or about April 29, 2022, when
8 Respondent's last review of Patient B's prescription history in the CURES database
9 was on or about August 28, 2020;

10 P. Issuing prescriptions for Adderall to Patient B on or about June 17, 2019, when
11 Respondent's last visit and/or assessment of Patient B was on or about February 7,
12 2019;

13 Q. Issuing prescriptions for Adderall to Patient B on or about July 11, 2019, when
14 Respondent's last visit and/or assessment of Patient B was on or about February 7,
15 2019;

16 R. Issuing prescriptions for Adderall to Patient B on or about August 9, 2019,
17 when Respondent's last visit and/or assessment of Patient B was on or about February
18 7, 2019;

19 S. Issuing prescriptions for Adderall to Patient B on or about September 9, 2019,
20 when Respondent's last visit and/or assessment of Patient B was on or about February
21 7, 2019;

22 T. Issuing prescriptions for Adderall to Patient B on or about October 17, 2019,
23 when Respondent's last visit and/or assessment of Patient B was on or about February
24 7, 2019;

25 U. Issuing prescriptions for Adderall to Patient B on or about November 15, 2019,
26 when Respondent's last visit and/or assessment of Patient B was on or about February
27 7, 2019;

28 ///

1 V. Issuing prescriptions for Adderall to Patient B on or about December 13, 2019,
2 when Respondent's last visit and/or assessment of Patient B was on or about February
3 7, 2019;

4 W. Issuing prescriptions for Adderall to Patient B on or about January 13, 2020,
5 when Respondent's last visit and/or assessment of Patient B was on or about February
6 7, 2019;

7 X. Issuing prescriptions for Adderall to Patient B on or about May 7, 2021, when
8 Respondent's last visit and/or assessment of Patient B was on or about January 8,
9 2021; and

10 Y. Issuing prescriptions for Adderall to Patient B on or about June 4, 2021, when
11 Respondent's last visit and/or assessment of Patient B was on or about January 8,
12 2021.

13 **Patient C**

14 32. On or about November 14, 2019, Patient C, a then 53-year-old female, first sought
15 treatment with Respondent. According to records, Patient C was diagnosed with major
16 depressive disorder with psychotic features. According to records, Patient C regularly received
17 and filled prescriptions issued by Respondent for clonazepam.

18 33. From on or about November 14, 2019, through on or about April 6, 2022, according
19 to records, Patient C had visits with, and was assessed by, Respondent on approximately seven
20 (7) occasions, including, but not limited to: November 14, 2019; February 13, 2020; May 21,
21 2020; July 31, 2020; March 25, 2021; October 7, 2021; and February 10, 2022.

22 34. From on or about November 14, 2019, through on or about April 6, 2022, according
23 to records, Respondent consulted the CURES database to review Patient C's patient activity
24 report on one (1) occasion: November 14, 2019.

25 35. From on or about February 13, 2020, through on or about April 6, 2022, according to
26 the CURES database, Patient C filled prescriptions issued by Respondent for clonazepam (0.5
27 mg), as follows:

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Date Filled	Drug Name	Strength	Days Supply	Quantity	Pharmacy Rx No.
2/13/2020	Clonazepam	0.5 mg	30	60	4458391
3/20/2020	Clonazepam	0.5 mg	30	60	4458391
5/21/2020	Clonazepam	0.5 mg	30	60	4458391
7/3/2020	Clonazepam	0.5 mg	30	60	4458862
7/30/2020	Clonazepam	0.5 mg	30	60	4458862
9/20/2020	Clonazepam	0.5 mg	30	60	4459055
11/9/2020	Clonazepam	0.5 mg	30	60	4459055
12/8/2020	Clonazepam	0.5 mg	30	60	4459055
3/4/2021	Clonazepam	0.5 mg	30	60	4459835
5/4/2021	Clonazepam	0.5 mg	30	60	179406
6/3/2021	Clonazepam	0.5 mg	30	60	179406
7/5/2021	Clonazepam	0.5 mg	30	60	179406
8/2/2021	Clonazepam	0.5 mg	30	60	186927
8/26/2021	Clonazepam	0.5 mg	30	60	186927
10/7/2021	Clonazepam	0.5 mg	30	60	195418
11/8/2021	Clonazepam	0.5 mg	30	60	195418
12/7/2021	Clonazepam	0.5 mg	30	60	201656
1/13/2022	Clonazepam	0.5 mg	30	60	205806
2/9/2022	Clonazepam	0.5 mg	30	60	205806
3/10/2022	Clonazepam	0.5 mg	30	60	211315
4/6/2022	Clonazepam	0.5 mg	30	60	211315

///
///
///

1 36. Respondent committed repeated negligent acts in his care and treatment of Patient C,
2 including, but not limited to, the following:

3 A. Paragraphs 32 through 35, above, are hereby incorporated by reference and
4 realleged as if fully set forth herein;

5 B. Issuing a prescription for clonazepam to Patient C on or about July 3, 2020,
6 when Respondent's last review of Patient C's prescription history in the CURES
7 database was on or about November 14, 2019;

8 C. Issuing a prescription for clonazepam to Patient C on or about September 20,
9 2020, when Respondent's last review of Patient C's prescription history in the
10 CURES database was on or about November 14, 2019;

11 D. Issuing a prescription for clonazepam to Patient C on or about March 4, 2021,
12 when Respondent's last review of Patient C's prescription history in the CURES
13 database was on or about November 14, 2019;

14 E. Issuing a prescription for clonazepam to Patient C on or about May 4, 2021,
15 when Respondent's last review of Patient C's prescription history in the CURES
16 database was on or about November 14, 2019;

17 F. Issuing a prescription for clonazepam to Patient C on or about August 2, 2021,
18 when Respondent's last review of Patient C's prescription history in the CURES
19 database was on or about November 14, 2019;

20 G. Issuing a prescription for clonazepam to Patient C on or about October 7, 2021,
21 when Respondent's last review of Patient C's prescription history in the CURES
22 database was on or about November 14, 2019;

23 H. Issuing a prescription for clonazepam to Patient C on or about December 7,
24 2021, when Respondent's last review of Patient C's prescription history in the
25 CURES database was on or about November 14, 2019;

26 I. Issuing a prescription for clonazepam to Patient C on or about January 13,
27 2022, when Respondent's last review of Patient C's prescription history in the
28 CURES database was on or about November 14, 2019;

1 J. Issuing a prescription for clonazepam to Patient C on or about March 10, 2022,
2 when Respondent's last review of Patient C's prescription history in the CURES
3 database was on or about November 14, 2019; and

4 K. Issuing a prescription for clonazepam to Patient C on or about March 4, 2021,
5 when Respondent's last visit and/or assessment of Patient C was on or about July 31,
6 2020.

7 **Patient D**

8 37. On or about June 4, 2020, Patient D, a then 46-year-old female, first sought treatment
9 with Respondent. According to records, Patient D was diagnosed with major depressive disorder
10 and anxiety with panic attacks. According to records, Patient D regularly received and filled
11 prescriptions issued by Respondent for alprazolam.

12 38. From on or about June 4, 2020, through on or about June 3, 2022, according to
13 records, Patient D had visits with, and was assessed by, Respondent on approximately eight (8)
14 occasions, including, but not limited to: June 4, 2020; July 31, 2020; October 9, 2020; November
15 20, 2020; January 7, 2021; February 25, 2021; April 22, 2021; and March 11, 2022.

16 39. From on or about June 4, 2020, through on or about June 3, 2022, according to
17 records, Respondent did not consult the CURES database to review Patient D's patient activity
18 report on any occasion.

19 40. From on or about July 12, 2020, through on or about April 18, 2022, according to the
20 CURES database, Patient D filled prescriptions issued by Respondent for alprazolam (1 mg), as
21 follows:

Date Filled	Drug Name	Strength	Days Supply	Quantity	Pharmacy Rx No.
7/12/2020	Alprazolam	1 mg	30	60	2072506
9/15/2020	Alprazolam	1 mg	30	60	2095197
10/9/2020	Alprazolam	1 mg	30	60	2103430
11/13/2020	Alprazolam	1 mg	30	60	2103430
12/13/2020	Alprazolam	1 mg	30	60	2095197

Date Filled	Drug Name	Strength	Days Supply	Quantity	Pharmacy Rx No.
1/11/2021	Alprazolam	1 mg	30	60	2103430
2/8/2021	Alprazolam	1 mg	30	60	2142675
3/1/2021	Alprazolam	1 mg	30	60	2148578
4/9/2021	Alprazolam	1 mg	30	60	2148578
5/3/2021	Alprazolam	1 mg	30	60	2148578
6/21/2021	Alprazolam	1 mg	30	60	2148578
7/29/2021	Alprazolam	1 mg	30	60	2199837
10/11/2021	Alprazolam	1 mg	30	60	2199837
3/11/2022	Alprazolam	1 mg	30	60	2283376
4/18/2022	Alprazolam	1 mg	30	60	2283376

41. Respondent committed repeated negligent acts in his care and treatment of Patient D, including, but not limited to, the following:

- A. Paragraphs 37 through 40, above, are hereby incorporated by reference and realleged as if fully set forth herein;
- B. Issuing a prescription for alprazolam to Patient D on or about July 12, 2020, without reviewing Patient D's prescription history in the CURES database;
- C. Issuing a prescription for alprazolam to Patient D on or about September 15, 2020, without reviewing Patient D's prescription history in the CURES database;
- D. Issuing a prescription for alprazolam to Patient D on or about October 9, 2020, without reviewing Patient D's prescription history in the CURES database;
- E. Issuing a prescription for alprazolam to Patient D on or about February 8, 2021, without reviewing Patient D's prescription history in the CURES database;
- F. Issuing a prescription for alprazolam to Patient D on or about March 1, 2021, without reviewing Patient D's prescription history in the CURES database;

1 G. Issuing a prescription for alprazolam to Patient D on or about July 29, 2021,
2 without reviewing Patient D's prescription history in the CURES database; and
3 H. Issuing a prescription for alprazolam to Patient D on or about March 11, 2022,
4 without reviewing Patient D's prescription history in the CURES database.

5 **SECOND CAUSE FOR DISCIPLINE**

6 **(Violation of State Statutes Regulating Controlled Substances)**

7 42. Respondent has further subjected his Physician's and Surgeon's Certificate No.
8 G 88320 to disciplinary action under sections 2227 and 2234, as defined by section 2238, of the
9 Code, in that he violated state statutes regulating controlled substances, including, but not limited
10 to, section 11165.4 of the Health and Safety Code, as more particularly alleged in paragraphs 18
11 through 41, above, which are hereby incorporated by reference and realleged as if fully set forth
12 herein.

13 **THIRD CAUSE FOR DISCIPLINE**

14 **(Violations of Provisions of the Medical Practice Act)**

15 43. Respondent has further subjected his Physician's and Surgeon's Certificate No.
16 G 88320 to disciplinary action under sections 2227 and 2234, as defined by section 2234,
17 subdivision (a), of the Code, in that he violated provisions of the Medical Practice Act, as more
18 particularly alleged in paragraphs 18 through 42, above, which are hereby incorporated by
19 reference and realleged as if fully set forth herein.

20 **PRAYER**

21 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
22 and that following the hearing, the Medical Board of California issue a decision:

- 23 1. Revoking or suspending Physician's and Surgeon's Certificate No. G 88320, issued
24 to Respondent Edward Harry Navakas, M.D.;
- 25 2. Revoking, suspending or denying approval of Respondent Edward Harry Navakas,
26 M.D.'s authority to supervise physician assistants and advanced practice nurses;

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

- 3. Ordering Respondent Edward Harry Navakas, M.D., to pay the Board the costs of the investigation and enforcement of this case, and if placed on probation, the costs of probation monitoring; and
- 4. Taking such other and further action as deemed necessary and proper.

DATED: SEP 28 2023



REJI VARGHESE
Executive Director
Medical Board of California
Department of Consumer Affairs
State of California
Complainant

SD2023802068
84121355